Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 17/20 | 0.75 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12214279 | 0.86 | ADAM17 (1.00) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8217816 | 0.86 | ADAM17 (1.00) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8217820 | 0.81 | ADAM17 (0.70) | ADAM17GRM1DRD2DRD4CHRM4 | |
| SCHEMBL8217827 | 0.81 | ADAM17 (0.70) | ADAM17GRM1DRD2DRD4CHRM4 | |
| SCHEMBL8275879 | 0.75 | ADAM17 (0.81) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8217862 | 0.74 | ADAM17 (0.60) | ADAM17ADAM10MMP13GRM1DRD2 | |
| SCHEMBL8275634 | 0.74 | ADAM17 (0.79) | ADAM17ADAM10MMP1MMP2MMP3 | |
| SCHEMBL8222061 | 0.73 | ADAM17 (0.59) | ADAM17CHRM4 | |
| SCHEMBL8213991 | 0.70 | ADAM17 (0.55) | ADAM17DRD2DRD4CHRM4 | |
| SCHEMBL8221185 | 0.69 | ADAM17 (0.67) | ADAM17ADAM10MMP1MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | ADAM17 11/4885ADAM10 13/4885MMP1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.